We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 07, 2020

No Benefit From Maintenance Gemcitabine Following Biweekly Gemcitabine and Carboplatin in Elderly Patients With Untreated NSCLC

The Oncologist


Additional Info

The Oncologist
Randomized Phase II Study of First-Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin Plus Maintenance Gemcitabine in Elderly Patients With Untreated Non-Small Cell Lung Cancer: LOGIK0801
Oncologist 2020 May 09;[EPub Ahead of Print], K Takayama, M Takeshita, K Inoue, M Ichiki, M Fujita, T Harada, Y Shiraishi, H Wataya, S Tokunaga, T Yamada, J Uchino, K Sugio

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading